Literature DB >> 16251335

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

M A Pfaller1, D J Diekema, L Boyken, S A Messer, S Tendolkar, R J Hollis, B P Goldstein.   

Abstract

In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. The anidulafungin MIC distribution showed that Candida albicans and C. glabrata were the most susceptible species and C. parapsilosis was the least susceptible species.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16251335      PMCID： PMC1280139          DOI： 10.1128/AAC.49.11.4795-4797.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

2.  In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.

Authors:  G Quindós; A J Carrillo-Muñoz; M P Arévalo; J Salgado; R Alonso-Vargas; J M Rodrigo; M T Ruesga; A Valverde; J Pemán; E Cantón; E Martín-Mazuelos; J Pontón
Journal:  Chemotherapy       Date:  2000 Nov-Dec       Impact factor: 2.544

3.  In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.

Authors:  M Chávez; S Bernal; A Valverde; M J Gutierrez; G Quindós; E M Mazuelos
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

4.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

Authors:  Shawn A Messer; Jeffrey T Kirby; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2004-11-25       Impact factor: 5.790

6.  Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Authors:  D J Diekema; S A Messer; A B Brueggemann; S L Coffman; G V Doern; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.

Authors:  C B Moore; K L Oakley; D W Denning
Journal:  Clin Microbiol Infect       Date:  2001-01       Impact factor: 8.067

8.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

9.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.

Authors:  María Pilar Arévalo; Alfonso-Javier Carrillo-Muñoz; Javier Salgado; Delia Cardenes; Sonia Brió; Guillermo Quindós; Ana Espinel-Ingroff
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790
View more
  18 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

3.  Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

4.  FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.

Authors:  Alicia J Zimbeck; Naureen Iqbal; Angela M Ahlquist; Monica M Farley; Lee H Harrison; Tom Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

5.  FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.

Authors:  Sofia Costa-de-Oliveira; Isabel Marcos Miranda; Raquel M Silva; Ana Pinto E Silva; Rita Rocha; António Amorim; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

6.  Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Emilio Mayayo; Guillermo Quindós; Alfonso J Carrillo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

7.  Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

8.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Authors:  D Andes; D J Diekema; M A Pfaller; R A Prince; K Marchillo; J Ashbeck; J Hou
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

10.  Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.

Authors:  Dimitra Dimopoulou; Georgios Hamilos; Maria Tzardi; Russell E Lewis; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.